Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 535

1.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
2.

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.

Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B.

Schizophr Res. 2009 Feb;107(2-3):115-21. doi: 10.1016/j.schres.2008.09.028. Epub 2008 Nov 6.

PMID:
18993033
3.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
4.

Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.

Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL.

Schizophr Res. 2008 Feb;99(1-3):13-22. Epub 2007 Dec 3.

PMID:
18053689
6.
7.

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.

Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, Crespo-Facorro B.

Int J Neuropsychopharmacol. 2014 Jan;17(1):41-51. doi: 10.1017/S1461145713001053. Epub 2013 Oct 8.

PMID:
24103107
8.

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP.

Ann Clin Psychiatry. 2008 Apr-Jun;20(2):71-8. doi: 10.1080/10401230802017050.

PMID:
18568578
9.

Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Ramirez-Bonilla M, Martínez-Garcia O, Pardo-Garcia G, Caseiro O, Pelayo-Terán JM, Vázquez-Barquero JL.

J Psychopharmacol. 2011 Jun;25(6):744-54. doi: 10.1177/0269881110388332. Epub 2011 Feb 3.

PMID:
21292922
10.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
11.

Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Caseiro O, Martínez-Garcia O, Pardo G, Ramirez-Bonilla M, Pelayo-Terán JM, Vázquez-Barquero JL.

J Psychiatr Res. 2011 Jun;45(6):763-9. doi: 10.1016/j.jpsychires.2010.11.002. Epub 2010 Nov 23.

PMID:
21106207
12.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
13.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
14.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
15.

Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.

Crespo-Facorro B, Rodríguez-Sánchez JM, Pérez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, Martínez-Garcia O, Vázquez-Barquero JL.

J Clin Psychiatry. 2009 Apr 21;70(5):717-29. doi: 10.4088/JCP.08m04634.

PMID:
19389335
16.

The effects of novel antipsychotics on glucose and lipid levels.

Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.

J Clin Psychiatry. 2002 Oct;63(10):856-65.

PMID:
12416594
17.

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.

Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G; Early Psychosis Global Working Group..

Am J Psychiatry. 2005 May;162(5):947-53.

PMID:
15863797
18.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group..

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
19.

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.

Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I; IC-SOHO Study Group..

J Clin Psychiatry. 2004 Mar;65(3):312-21.

PMID:
15096069
20.

Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.

Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S.

J Clin Psychiatry. 2009 Nov;70(11):1501-13. doi: 10.4088/JCP.08m04446yel. Epub 2009 Oct 6.

PMID:
19814947

Supplemental Content

Support Center